(Q34742649)

4 August 2017

Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategies (English)

1 reference

Constantino Carlos Reyes-Aldasoro

4 August 2017

0 references

object named as

Constantino C Reyes-Aldasoro

5

0 references

Sarah Jane Lunt

6

object named as

Sarah Jane Lunt

1 reference

4 August 2017

Borivoj Vojnovic

13

0 references

Gillian Tozer

15

object named as

Gillian M Tozer

1 reference

4 August 2017

Simon Akerman

1

1 reference

4 August 2017

Matthew Fisher

2

1 reference

4 August 2017

Rachel A Daniel

3

1 reference

4 August 2017

Diane Lefley

4

1 reference

4 August 2017

Sheila Harris

7

1 reference

4 August 2017

Meit Bjorndahl

8

1 reference

4 August 2017

Leigh J Williams

9

1 reference

4 August 2017

Helen Evans

10

1 reference

4 August 2017

Paul R Barber

11

1 reference

4 August 2017

Vivien E Prise

12

1 reference

4 August 2017

Chryso Kanthou

14

1 reference

4 August 2017

language of work or name

English

0 references

publication date

10 July 2013

1 reference

International Journal of Cancer

4 August 2017

1 reference

4 August 2017

133

1 reference

4 August 2017

11

1 reference

4 August 2017

2563-2576

1 reference

VEGF-targeted therapy: mechanisms of anti-tumour activity.

4 August 2017

1 reference

Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer

21 January 2018

1 reference

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

21 January 2018

1 reference

Normalization of the vasculature for treatment of cancer and other diseases

21 January 2018

1 reference

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

21 January 2018

1 reference

SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells

21 January 2018

1 reference

Indolinones and anilinophthalazines differentially target VEGF-A- and basic fibroblast growth factor-mediated responses in primary human endothelial cells.

21 January 2018

1 reference

Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy

21 January 2018

1 reference

Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment

21 January 2018

1 reference

Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis

21 January 2018

1 reference

Isoforms of vascular endothelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature.

21 January 2018

1 reference

Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.

21 January 2018

1 reference

The biology of VEGF and its receptors

21 January 2018

1 reference

Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer

21 January 2018

1 reference

Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression

21 January 2018

1 reference

Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells

21 January 2018

1 reference

Guidelines for the welfare and use of animals in cancer research

21 January 2018

1 reference

An automatic algorithm for the segmentation and morphological analysis of microvessels in immunostained histological tumour sections.

21 January 2018

1 reference

Interstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumours

21 January 2018

1 reference

Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy

21 January 2018

1 reference

Measuring the velocity of fluorescently labelled red blood cells with a keyhole tracking algorithm.

21 January 2018

1 reference

Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to vascular targeting agents.

21 January 2018

1 reference

Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.

21 January 2018

1 reference

Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.

21 January 2018

1 reference

Tumor vascular changes mediated by inhibition of oncogenic signaling

21 January 2018

1 reference

Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action

21 January 2018

1 reference

Tumour vascular disrupting agents: combating treatment resistance

21 January 2018

1 reference

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.

21 January 2018

1 reference

TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice

21 January 2018

1 reference

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28281

1 reference

4 August 2017

1 reference